...Thank you, Sarah. Ladies and gentlemen, a warm welcome to this conference call from all of us here at CureVac. In this presentation, we will provide you with an overview of our recently announced COVID-19 partnerships and the synergies being created by joining our respective expertise to provide broader and faster protection against the current and future viral infections and threats. We all believe these collaborations will create short-term and long-term value for our company. Since development of our first mRNA-based COVID-19 vaccines began 1 year ago, the world has made tremendous advances to better understand the nature of the virus. mRNA technology has emerged as a key technology to rapidly provide potent, flexible and easy-to-manufacture vaccines. And that, without a doubt, will have a long-lasting impact on the way we will globally address and prepare for future preparedness and for the vaccine development in general....
